IDTs San Diego, California, Manufacturing Facility Receives ISO 14001 Certification
![](/46/pdcnewsitem/03/44/15/CyusZOUHu3ap5FX.png)
Integrated DNA Technologies (IDT) has announced that its San Diego, California, manufacturing facility has attained ISO 14001:2004 certification for its environmental management systems. Now, both of IDT’s US manufacturing sites (Coralville, IA and San Diego, CA) have ISO 14001 certified environmental management systems. The Coralville facility was first certified in 2012 and recertified in 2014.
In honor of the San Diego facility’s achievement, the company is launching the IDT ISO 14001 Sustainability Award, Earth Day. The contest for the inaugural award is focused on biodiversity and is open to all academic researchers in Southern California. Future awards may focus on other regions and other areas of study. The award recipient will receive $14,001 worth of Oligo Credit from IDT. Submission deadline is 15 June 2015, and the winner will be announced during a special event hosted at IDT’s San Diego facility on 18 August 2015.
Dan Dernbach, General Manager of IDT’s West Coast Operations, said attaining certification was a team effort. “ISO 14001 certification solidifies our commitment to meet the highest standard of environmental accountability. We are proud of our employees’ dedication to reducing our energy consumption and water usage while increasing our recycling efforts and our use of recyclable materials. We have also reduced the use of solvents and minimized the creation of hazardous waste.”
Dr Joseph A. Walder, IDT founder and CEO, agrees: “This certification is an important milestone for our San Diego facility. The site has grown significantly since its opening in 2005. In 2014 alone, we achieved double digit growth in both production and revenue, and increased the number of staff 20%. Attaining ISO 14001 certification while also further developing our business demonstrates our commitment to both sound environmental sustainability and responsible economic growth.”
“What better way to acknowledge the San Diego facility’s ISO 14001 achievement than to advance local research efforts at discovery in biodiversity,” said Dr Mark Behlke, IDT’s Chief Scientific Officer. “With this award, we hope to encourage and support innovative solutions that make a difference in our local communities and for our planet.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance